What Is Zepbound and How Does It Work
Zepbound (tirzepatide) is an FDA-approved injectable for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Unlike semaglutide-based medications that target only the GLP-1 receptor, tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two appetite-regulating pathways simultaneously.
In clinical trials, Zepbound demonstrated impressive weight loss results. Participants on the highest dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks — significantly more than placebo. The medication is administered as a once-weekly subcutaneous injection, with doses escalating from 2.5 mg up to 15 mg over several months.
Getting Zepbound Through Telehealth
The telehealth process for Zepbound mirrors that of other GLP-1 medications. You start by completing a detailed health questionnaire covering your weight history, BMI, medical conditions, and current medications. A licensed prescriber then evaluates your eligibility — either through a video visit or an asynchronous review, depending on the platform and your state's regulations.
If approved, the prescription is sent to a pharmacy. Many telehealth platforms work with specialty mail-order pharmacies that ship Zepbound directly to your home in temperature-controlled packaging. Your provider schedules regular follow-up appointments, typically monthly, to track your progress, adjust dosing, and manage any side effects during the escalation period.
Cost, Insurance, and Savings Programs
Zepbound's retail price is approximately $1,060 per month without insurance. Coverage varies by insurer and plan. Many commercial plans have added Zepbound to their formularies, but prior authorization is standard practice. Some employers have excluded weight-loss medications from their benefits, so it is worth checking your specific coverage details before starting.
Eli Lilly offers a savings card program for eligible commercially insured patients that can reduce copays significantly. For cash-pay patients, several telehealth platforms have negotiated pricing arrangements or offer their own compounded tirzepatide options at lower price points. Telehealth consultation fees typically range from $99 to $299 per month, separate from the medication cost.
Zepbound vs. Mounjaro: Understanding the Difference
Both Zepbound and Mounjaro contain tirzepatide and are manufactured by Eli Lilly, but they are approved for different indications. Mounjaro is indicated for type 2 diabetes management, while Zepbound is specifically approved for chronic weight management. The medication itself is identical; the difference lies in the FDA-approved indication, which affects insurance coverage and prescribing protocols. Your telehealth provider will prescribe the appropriate product based on your medical history and diagnosis.
Choosing a Telehealth Provider for Zepbound
When evaluating telehealth platforms for Zepbound, key differentiators include whether they prescribe branded Zepbound (versus compounded tirzepatide), their state coverage, insurance navigation support, and the comprehensiveness of their weight management program. The best programs combine the prescription with dietary guidance, exercise recommendations, and behavioral coaching for sustainable results. Explore the GLP-1 providers listed below to find a platform that fits your needs and location.
